New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ARRY;NVS;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 1, 2015
15:14 EDTNVSExpress Scripts in settlement pact related to alleged Novartis kickbacks
Accredo Health, a wholly-owned subsidiary of Express Scripts (ESRX), entered a settlement and dismissal agreement with United States Attorney for the Southern District of New York, Preet Bharara, related to Accredo's alleged involvement in Novartis's (NVS) alleged participation in a kickback scheme involving Exjade, according to a court filing. In settlement of the United States' claims against Accredo in this action, Accredo shall pay to the United States a sum just over $45M, according to the court filing. A recent filing with the SEC noted that a total of $60M was set aside by Express Scripts to resolve the allegations with the federal government and all 50 states and a company spokesman confirmed the settlement involves $60M, according to The Wall Street Journal. Reference Link
07:43 EDTNVS, AZNExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
10:46 EDTARRYLeerink biotech analyst holds an analyst/industry conference call
Biotech Analyst Liang, along with Dr. Alan List an MDS Specialist, provide an update on the myelodysplastic syndrome pipeline on an Analyst/Industry conference call to be held on May 5 at 2:30 pm.
April 29, 2015
10:39 EDTAZNCiti analyst says outlook still strong for big pharma
Subscribe for More Information
07:18 EDTAZNAstraZeneca says FDA grants priority review for new indication of Brilinta
AstraZeneca announced that the FDA has accepted a supplemental new drug application and granted Priority Review for BRILINTA tablets for patients with a history of heart attack. The sNDA is based on the results of the PEGASUS-TIMI 54 study, a large-scale outcomes trial in more than 21,000 patients that investigated ticagrelor tablets plus low dose aspirin, compared to placebo plus low dose aspirin, for the chronic secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study enrollment. The Prescription Drug User Fee Act goal date will be in the third quarter of 2015. A Priority Review designation is granted to medicines that the FDA determines have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. PEGASUS-TIMI 54 is part of AstraZeneca’s PARTHENON program. The PLATO study, involving over 18,000 patients, was the first study in the program and is the basis on which ticagrelor has been approved in over 100 countries and included in 12 major ACS treatment guidelines globally. Further ongoing PARTHENON studies are assessing ticagrelor for the prevention of cardiovascular events in patients with peripheral arterial disease, ischemic stroke or transient ischemic attack, and in patients with diabetes and coronary atherosclerosis. BRILINTA is not approved for secondary prevention of atherothrombotic events in patients with a history of heart attack beyond one year or for the prevention of cardiovascular events in patients with peripheral arterial disease, stroke, diabetes or atherosclerosis.
April 27, 2015
12:28 EDTARRYOptions with increasing implied volatility
Options with increasing implied volatility: THRX ARRY AKRX DECK HSBC
10:30 EDTNVSNovartis says Phase III Arzerra study met primary endpoint
Subscribe for More Information
08:41 EDTAZNTelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTNVS, AZNPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
06:19 EDTAZNAstraZeneca says smaller M&A deals more realistic, Reuters reports
Subscribe for More Information
06:07 EDTAZNAstraZeneca reiterates outlook for FY15
Subscribe for More Information
06:06 EDTAZNAstraZeneca reports Q1 core EPS $1.08, consensus $1.05
Reports Q1 revenue $6.06B, consensus $5.95B. Reports Q1 Symbicort revenue $845M vs. $928M last year, Pulmicort revenue $286M vs. $263M last year, Crestor revenue $1.17B vs. $1.33B last year, Nexium revenue $644M vs. $930M last year.
05:39 EDTAZNCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
05:37 EDTAZNAstraZeneca signs co-development agreement with Innate Pharma
Subscribe for More Information
April 23, 2015
15:01 EDTAZNNotable companies reporting before tomorrow's open
Subscribe for More Information
09:52 EDTNVSEli Lilly sees at least $200M in savings from Novartis Animal Health acquisition
08:25 EDTAZNJuno Therapeutics, MedImmune announce immuno-oncology trial collaboration
Subscribe for More Information
05:25 EDTNVSNovartis backs FY15 revenue guidance of growth in mid-single digits
Subscribe for More Information
05:22 EDTNVSNovartis reports Q1 Core EPS $1.33, consensus $1.10
Subscribe for More Information
April 22, 2015
08:04 EDTAZNBIND Therapeutics presents data on BIND-014, AZD2811 at AACR
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use